

## ICMJE DISCLOSURE FORM

Date: 30<sup>th</sup> November 2023

Your Name: Silvia Casacuberta-Serra

Manuscript Title: eIF4A dependency: The hidden key to unlock KRAS mutant NSCLC's vulnerability

Manuscript number (if known): TLCR-23-682

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the **current manuscript only**.

The author's relationships/activities/interests should be **defined broadly**. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Spanish Ministry of Economy and Competitiveness	Proyectos de I+D+i en Líneas Estratégicas" (PLEC2021-007959) grant
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	___ None	
3	Royalties or licenses	___ None	
4	Consulting fees	___ None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	____ None	
6	Payment for expert testimony	____ None	
7	Support for attending meetings and/or travel	____ None	
8	Patents planned, issued or pending	EP20710558	
		EP22383031	
		EP23382345	
		EP23382552	
9	Participation on a Data Safety Monitoring Board or Advisory Board	____ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Peptomyc S.L.	SCS is employee of the company
11	Stock or stock options	Peptomyc S.L.	SCS is a shareholder of the company
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	____ None	
13	Other financial or non-financial interests	____ None	

**Please summarize the above conflict of interest in the following box:**

Sílvia Casacuberta-Serra reports that she received support from Spanish Ministry of Economy and Competitiveness [Proyectos de I+D+i en Líneas Estratégicas” (PLEC2021- 007959) grant]; she is the author of patents directly or indirectly connected to lung cancer treatment (EP20710558, EP22383031, EP23382345 and EP23382552); she is the employee and shareholder of Peptomyc S.L., a company that develops therapeutics for cancer treatment.

**Please place an “X” next to the following statement to indicate your agreement:**

**X I certify that I have answered every question and have not altered the wording of any of the questions on this form.**

## ICMJE DISCLOSURE FORM

Date: 30<sup>th</sup> November 2023

Your Name: Íñigo González-Larreategui

Manuscript Title: eIF4A dependency: The hidden key to unlock KRAS mutant NSCLC's vulnerability

Manuscript number (if known): TLCR-23-682

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	BBVA Foundation	2nd Comprehensive Program of Cancer Immunotherapy & Immunology (CAIMI-II) grant
		Spanish Ministry of Universities	Grant from the University Teacher Training Program FPU (FPU20/04812)
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	___ None	
3	Royalties or licenses	___ None	
4	Consulting fees	___ None	

5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None	
6	Payment for expert testimony	None	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or pending	EP23382552	
9	Participation on a Data Safety Monitoring Board or Advisory Board	None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
11	Stock or stock options	None	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
13	Other financial or non-financial interests	None	

**Please summarize the above conflict of interest in the following box:**

Íñigo González-Larreategui reports that he received support from BBVA Foundation [2nd Comprehensive Program of Cancer Immunotherapy & Immunology (CAIMI-II) grant] and Spanish Ministry of Universities [Grant from the University Teacher Training Program FPU (FPU20/04812)] and he is the author of one patent connected to lung cancer treatment (EP23382552).

**Please place an “X” next to the following statement to indicate your agreement:**

I certify that I have answered every question and have not altered the wording of any of the questions on this form

## ICMJE DISCLOSURE FORM

Date: 1st December 2023

Your Name: Laura Soucek

Manuscript Title: eIF4A dependency: The hidden key to unlock KRAS mutant NSCLC's vulnerability

Manuscript number (if known): TLCR-23-682

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
<b>Time frame: Since the initial planning of the work</b>			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) <b>No time limit for this item.</b>	Spanish Ministry of Economy and Competitiveness	Proyectos de I+D+i en Líneas Estratégicas" (PLEC2021-007959) grant
		La Marató TV3	grant (2019429)
		BBVA Foundation	2nd Comprehensive Program of Cancer Immunotherapy & Immunology (CAIMI-II) grant
<b>Time frame: past 36 months</b>			
2	Grants or contracts from any entity (if not indicated in item #1 above).	___ None	
3	Royalties or licenses	___ None	

4	Consulting fees	Peptomyc S.L.	L.S. was a consultant for Peptomyc S.L.
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	____ None	
6	Payment for expert testimony	____ None	
7	Support for attending meetings and/or travel	____ None	
8	Patents planned, issued or pending	EP13382167	
		EP16382339	
		EP19382195	
		EP19382194	
		EP22383031	
		EP22383028	
		EP23382345	
		EP23382552	
		EP23382553	
		EP2338255	
9	Participation on a Data Safety Monitoring Board or Advisory Board	____ None	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	Peptomyc S.L.	LS is CEO of the company
11	Stock or stock options	Peptomyc S.L.	LS is a shareholder of the company
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	____ None	
13	Other financial or non-financial interests	____ None	

**Please summarize the above conflict of interest in the following box:**

Laura Soucek reports she received support from the Spanish Ministry of Economy and Competitiveness [Proyectos de I+D+i en Líneas Estratégicas" (PLEC2021- 007959) grant], La Marató TV3 [grant (2019429)] and BBVA Foundation [2nd Comprehensive Program of Cancer Immunotherapy & Immunology (CAIMI-II) grant]; she is the CEO and shareholder of Peptomyc S.L., a company that develops therapeutics for cancer treatment, and received consulting fees from it; she is the author of patents directly or indirectly connected to lung cancer treatment (EP13382167, EP16382339, EP19382195, EP19382194, EP22383031, EP22383028, EP23382345, EP23382552, EP23382553 and EP2338255).

**Please place an "X" next to the following statement to indicate your agreement:**

I certify that I have answered every question and have not altered the wording of any of the questions on this form.